~~<i id='96B67CB5AD'><strike id='96B67CB5AD'><tt id='96B67CB5AD'><pre id='96B67CB5AD'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：entertainment 2025-10-02 23:47:26 - browse：8

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Can U.S. cancer drug shortages be fixed?

focus

knowledge

leisure time

hotspot

leisure time

AchildreceivesaCovid-19vaccinationinNeedham,Mass.JOSEPHPREZIOSO/AFPviaGettyImagesWithlastfall’schaot

WSS

People can get long Covid without testing positive for virus: Study

Why are Kaiser Permanente staff considering a strike?

CDC advisers recommend seasonal use of Pfizer RSV shot

Biotech stock slump in 2023: awaiting the turnaround

CDC advisers recommend seasonal use of Pfizer RSV shot

Second xenotransplant done with gene

focus

entertainment

focus

Supreme Court strikes down use of affirmative action

Can U.S. cancer drug shortages be fixed?

Activists slam private health insurers over coverage restrictions

California store owner shot dead in dispute over displaying Pride flag: Police

Medicare proposal to cover medical devices draws a mixed reaction

CommonSpirit Health keeps growing, even as it loses money

Anesthesiologist group: stop taking Ozempic before surgery

FDA advisory panel to debate high blood pressure devices

Activists slam private health insurers over coverage restrictions

Study: Spinal cord stimulation helps patients with paralysis walk again

knowledge

PBMs are inflating the cost of generic drugs. They must be reined in

How AI helped researchers track recovery from depression

Roche's accidental data boosts hopes for anti

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Vivek Ramaswamy made waves in the debate, much as in biotech

Senate HELP committee spars over health care workforce policies

leisure time

leisure time

hotspot

leisure time